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Low Resistin Level is Associated with Poor Hospitalization-Free 
Survival in Hemodialysis Patients
Malnutrition and inflammation are related to high rates of morbidity and mortality in 
hemodialysis patients. Resistin is associated with nutrition and inflammation. We 
attempted to determine whether resistin levels may predict clinical outcomes in 
hemodialysis patients. We conducted a prospective evaluation of 100 outpatients on 
hemodialysis in a single dialysis center (male, 46%; mean age, 53.7 ± 16.4 yr). We 
stratified the patients into 4 groups according to quartiles of serum resistin levels. During 
the 18-month observational period, patients with the lowest quartile of serum resistin 
levels had poor hospitalization-free survival (log rank test, P = 0.016). After adjustment of 
all co-variables, patients with the lowest quartile of serum resistin levels had poor 
hospitalization-free survival, compared with reference resistin levels. Higher levels of 
interleukin-6 were an independent predictor of poor hospitalization-free survival. In 
contrast, serum resistin levels were not correlated with interleukin-6 levels. The current 
data showed that low resistin levels may independently predict poor hospitalization free 
survival in hemodialysis patients.
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INTRODUCTION
Morbidity and mortality in patients on hemodialysis is still high 
despite significant improvement in dialysis technology (1). Their 
hospitalization may give rise to increasing individual and socio-
economical burden. Malnutrition and inflammation are related 
to high rates of morbidity and mortality in patients on hemodi-
alysis (2, 3). Serum levels of interleukin 6 (IL-6), leptin and adi-
ponectin are known to be elevated in dialysis patients (4-6), and 
have been associated with morbidity and mortality of dialysis 
patients through an endothelial injury, pathophysiology of ath-
erosclerotic vascular disease.
  Resistin, one of the adipocytokine, is from inflammatory cells 
infiltrating fat tissue, not directly from adipocytes (7). It causes 
impairment of glucose tolerance in mice; however, this physio-
logic role is not related to insulin resistance in humans. Instead, 
it is known to have an association with inflammation, patient’s 
nutrition, and residual renal function on hemodialysis (7, 8). 
However, few studies on the effect of resistin on clinical outcomes 
in dialytic patients have been conducted. Therefore, we attempt-
ed to determine whether resistin levels may independently pre-
dict clinical outcomes in hemodialysis patients.
MATERIALS AND METHODS
We enrolled adult outpatients on hemodialysis at the Gachon 
University of Medical and Science Gil Hospital, Korea. Patients 
who had started on dialysis for less than 3 months, had a recent 
history of infection, malignancy, amyloidosis or structural heart 
disease, or cardiovascular events, or had a life-expectancy of 
less than 6 months for any reason were excluded from this study. 
A total of 100 adult patients on hemodialysis was enrolled for 
analysis. All the patients were dialyzed with bio-compatible mem-
branes (F5 or F6; Fresenius Medical Care AG, Bad Homberg, 
Germany) using Fresenius 4008H (Fresenius Medical Care AG). 
Ninety seven patients underwent regular dialysis three times 
per week and 3 patients underwent regular dialysis two times 
per week. Ninety-six patients were anuric.
  We prospectively observed all hospitalization events as well 
as demographic and laboratory data over an 18-month period. 
Hospitalization was defined as any hospitalization events, regard-
less of causes for admission, with more than one overnight stay. 
The primary clinical outcome was hospitalization-free survival, 
and the secondary clinical outcomes were annual hospitaliza-
tion days and annual hospitalization frequency. Hospitalization-Chung W, et al.  •  Resistin and Hospitalization in Hemodialysis Patients
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free survival was defined as time to first hospitalization in pro-
spective period. Annual hospitalization days were the days of 
all hospital stay per year, expressed as days per patient-year. An-
nual hospitalization frequency was defined as number of hos-
pital admissions per year, expressed as times per patient-year. 
Causes of hospitalization included 5 categories; infection-relat-
ed events, dialysis-related events (hyperkalemia, vascular ac-
cess related events, volume overload/dehydration), cardiovas-
cular event, bone-related disorder (fracture and parathyroidec-
tomy) and other events.
  All of the laboratory parameters were measured in patients 
starting a mid-week dialytic session. Fasting blood samples were 
drawn from the arterial end of the vascular access just before 
starting hemodialysis. Serum samples were taken and centri-
fuged; supernatants were separated and immediately frozen at 
-70°C for later analysis. Serum urea nitrogen, creatinine, hemo-
globin, albumin, total cholesterol, triglyceride, and other bio-
chemistry parameters were measured by standard laboratory 
techniques using an automatic analyzer (ADVIA 2004 Chemis-
try system [Siemens, Diagnostics, Tarrytown, IL, USA]). Single 
pool Kt/Vurea was calculated using the Daugirdas equation and 
normalized protein nitrogen appearance by Depner and Daugir-
das (9, 10).
  For survival analysis, patients were divided according to quar-
tiles based on the serum levels of resistin. Resistin levels were 
determined using the Bio-Plex Pro human diabetes assay (Bio-
rad Laboratories, Hercules, CA, USA). Serum IL-6 concentra-
tion was analyzed using the Bio-Plex multiplex cytokine assay 
(Biorad Laboratories).
Statistical analysis
Data were reported as mean ± SD or number (percentage). Pa-
rameters among the 4 separated groups were analyzed using 
the Kruskal-Wallis test. Survival analyses were performed using 
Kaplan-Meier and the Cox proportional hazard model was ap-
plied to adjust for co-variables, including age, sex, diabetes mel-
litus, body mass index (BMI), serum albumin, normalized pro-
tein nigtrogen appearance (nPNA), hemodialysis duration, Kt/
Vurea, hemoglobin, erythropoietin resistance index, and IL-6 
levels. Parameters that did not demonstrate a Gaussian distri-
bution were logarithmically transformed. Data analysis was con-
ducted using SPSS 11.0 for Windows (SPSS Inc., Chicago, IL, 
USA). A P < 0.05 was considered statistically significant.
 
Ethics statement
Informed consent was obtained from all study participants. The 
study was approved from the local institutional review board of 
Gachon University Gil Hospital (IRB approval number: GIR-
BA2067).
RESULTS
Baseline characteristics are listed in Table 1. The mean age of 
patients was 53.7 ± 16.3 yr, male 46%, and the mean hemodial-
ysis vintage was 4.3 ± 4.4 yr. Fifty three percent of patients had 
diabetes mellitus. Mean resistin levels were 10.0 ± 0.43 ng/mL. 
Patient groups were divided according to each quartile of resis-
tin levels (Table 1). There were no significant differences in age, 
gender, body mass index, biochemical data, hematologic data, 
Table 1. Baseline characteristics according to each quartile of serum resistin level 
Characteristics Total patients
Quartile (resistin, pg/mL)
P value
1st (n = 25) 2nd (n = 25) 3rd (n = 25) 4th (n = 25)
Age (yr) 53.7 ± 16.3 52.0 ± 10.9 53.6 ± 21.8 54.2 ± 11.2 55.0 ± 19.3 0.929
Male (%) 46 (46) 12 (48) 8 (32) 12 (48) 14 (56) 0.383
Body mass index (kg/m
2) 22.0 ± 3.72 20.9 ± 2.65 21.6 ± 4.18 23.5 ± 4.54 21.8 ± 2.87 0.085
Dialysis parameters
   Hemodialysis vintage (yr)
   nPNA (g/kg/day) 
   Kt/Vurea 
 
4.28 ± 4.39
1.03 ± 0.22 
1.51 ± 0.30
 
3.79 ± 3.71
0.91 ± 0.15 
1.49 ± 0.36
 
4.30 ± 4.19
1.03 ± 0.19 
1.59 ± 0.24
 
5.08 ± 5.39
1.11 ± 0.18 
1.48 ± 0.21
 
3.94 ± 4.24
1.06 ± 0.29
1.50 ± 0.38
 
0.738
0.031
0.574 
Biochemical data 
   Albumin (g/dL) 
   Calcium (mg/dL) 
   Phosphorus (mg/dL) 
   Total cholesterol (mg/dL) 
   Triglyceride (mg/dL) 
   PTH (pg/mL) 
   Interleukin-6 (log[pg/mL])
   Adiponectin (log[pg/dL])
   Resistin (log[ng/mL])
 
3.80 ± 0.39
8.21 ± 0.80
4.85 ± 1.52
 148 ± 32.6
121 ± 72.7
189 ± 214
1.45 ± 0.59
14.8 ± 1.11
10.0 ± 0.43
 
3.78 ± 0.46
8.13 ± 0.68
5.06 ± 1.48
 146 ± 36.3
 107 ± 57.2
180 ± 301
1.24 ± 0.42
14.8 ± 1.09
9.55 ± 0.18
 
3.77 ± 0.36
8.24 ± 0.51
4.57 ± 1.53
 150 ± 30.7
 118 ± 54.1
192 ± 165
1.59 ± 0.61
14.7 ± 1.01
9.85 ± 0.07
 
3.87 ± 0.37
8.46 ± 0.70
4.78 ± 1.32
147 ± 32.9
135 ± 100
199 ± 206
1.46 ± 0.58
14.9 ± 1.22
10.1 ± 0.11
 
3.79 ± 0.37
8.00 ± 1.14
5.00 ± 1.76
 148 ± 32.1
 123 ± 71.5
185 ± 175
1.52 ± 0.68
14.7 ± 1.15
10.6 ± 0.21
 
0.786
0.223 
0.662 
0.986 
0.605 
0.992 
0.168
0.918
< 0.001
Hematologic data 
   Hemoglobin (g/dL) 
   Iron (µg/dL) 
   TIBC (µg/dL) 
   Ferritin (pg/mL) 
 
10.3 ± 0.83
72.1 ± 32.4
 265 ± 55.5
320 ± 237
 
10.4 ± 0.74
60.0 ± 25.2
 248 ± 35.6
342 ± 235
 
10.1 ± 0.93
73.6 ± 35.1
 268 ± 45.7
275 ± 171
 
10.5 ± 0.66
76.8 ± 29.2
 281 ± 87.6
330 ± 251
 
10.1 ± 0.95
78.2 ± 38.4
 264 ± 28.9
335 ± 284
 
0.322
0.299 
0.324 
0.744
nPNA, normalized protein nitrogen appearance; PTH, parathyroid hormone; TIBC, total iron bind capacity.Chung W, et al.  •  Resistin and Hospitalization in Hemodialysis Patients
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and dialysis parameters between the four groups. However, 
nPNA appeared to show a statistically significant increase ac-
cording to quartile of serum resistin (P = 0.031).
  There were 133 admission events and 2,096 admission days 
in 100 patients. Mean observational periods were 585 days. A 
total of 54 patients experienced at least one more admission 
events during the observational period. Two patients died and 
1 patient underwent kidney transplantation during the obser-
vational period. Hospitalization events included 28.5% for infec-
tion-related events, 12.2% for dialysis-related events, 11.3% for 
vascular access related events, 8.1% for cardiovascular events, 
1.6% for bone-related disorder, and 38.2% for other events (oph-
thalmic surgery, endoscopic procedure, and adverse effect of 
medication).
  Hospitalization-free survival according to quartile of serum 
resistin is shown in Fig. 1. We defined the second quartile group 
as reference, the patients with the lowest quartile of serum re-
sistin levels had poor hospitalization-free survival (P = 0.016). 
Low serum resistin levels, nPNA, hemodialysis vintage, diabe-
tes mellitus, hemoglobin, and IL-6 were significant predictors 
for all-cause hospitalization in univariable analysis. After adjust-
ment of all co-variables, lowest quartile of serum resistin levels, 
higher levels of serum IL-6, and presence of diabetes mellitus 
were found to independently increase the probability for hospi-
talization (Table 2). 
  Annual hospitalization frequency and hospitalization days 
were 0.62 ± 1.05 times per patient-year and 8.11 ± 21.5 days per 
patient-year. Among these patients, frequency of annual hospi-
talization and hospitalization days of patients with the lowest 
quartile of serum resistin level were 0.81 ± 0.83 times per patient-
year and 10.19 ± 19.6 days per patient-year. Annual hospitaliza-
tion frequency and annual hospitalization days appeared to be 
high in patients with the lowest quartile of serum resistin levels; 
however, they were not statistically significant (Table 3). nPNA 
showed positive correlation with serum resistin levels (Fig. 2). 
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Fig. 1. Hospitalization-free survival according to quartiles of serum resistin levels. 
Table 2. Cox regression analysis of baseline parameters for hospitalization-free survival
Parameters
Univariable analysis Multivariable analysis
P 
Hazard ratio  
(95% confidence interval)
P 
Hazard ratio  
(95% confidence interval)
Resistin
   (2nd quartile) 
   (1st quartile) 
   (3rd quartile) 
   (4th quartile) 
 
0.022
0.010 
0.984
0.316
  
Reference 
    2.645 (1.262 ± 5.543)
    0.991 (0.421 ± 2.334)
    1.498 (0.680 ± 3.300)
 
< 0.001
< 0.001
0.984
0.650
 
Reference 
4.302 (1.940 ± 9.540)
1.009 (0.419 ± 2.428)
1.216 (0.523 ± 2.830)
Age (1-yr increment)  0.835     0.998 (0.983 ± 1.014) 0.370 0.993 (0.979 ± 1.008)
Sex (male to female)  0.577     0.859 (0.504 ± 1.465) 0.992 1.003 (0.571 ± 1.761)
Body mass index (kg/m
2)  0.794     1.009 (0.944 ± 1.078) - 
Albumin (g/dL)  0.213     0.631 (0.306 ± 1.303) - 
nPNA (g/kg/day)  0.040     0.267 (0.076 ± 0.944) 0.732 0.812 (0.246 ± 2.678)
Hemodialysis duration  0.041     0.927 (0.861 ± 0.997) 0.429 0.970 (0.899 ± 1.046)
Diabetes (yes or no)  0.003     2.384 (1.352 ± 4.201) 0.038 1.999 (1.037 ± 3.852)
Hemoglobin (g/dL)  0.033     0.723 (0.537 ± 0.974) 0.180 0.809 (0.594 ± 1.103)
Interleukin-6 (log[pg/mL]) 0.002  2.116 (1.323-3.385)  0.001 2.671 (1.506 ± 4.737)
Adiponectin (log[pg/dL]) 0.474     1.087 (0.865 ± 1.366) - 
nPNA, normalized protein nitrogen appearance.
Table 3. Annual hospitalization frequency and days according to quartiles of resistin
Parameters Total patients
Quartile (resistin, pg/mL)
P
1st (n = 25) 2nd (n = 25) 3rd (n = 25) 4th (n = 25)
Annual hospitalization frequency  0.62 ± 1.05 0.81 ± 0.83 0.63 ± 1.63 0.39 ± 0.68 0.63 ± 0.79 0.665
Annual hospitalization days 8.11 ± 21.5 10.1 ± 19.6 5.18 ± 16.9 11.8 ± 34.3 5.36 ± 7.78 0.692Chung W, et al.  •  Resistin and Hospitalization in Hemodialysis Patients
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Serum albumin, BMI, and IL-6 did not show significant corre-
lation with serum resistin levels.
   
DISCUSSION
We demonstrated that the lowest quartile of serum resistin level 
predicted hospitalization-free survival, and that it was indepen-
dent of other inflammatory cytokines. Although some studies 
have demonstrated an association of serum resistin levels with 
inflammation, renal function, and nutrition, respectively (8, 11-
14), few studies reported on the direct relationship between re-
sistin levels and clinical outcomes. 
  Resistin is comprised of 108 amino acid peptide molecules; 
its weight is 12.5 kDa. The kidney is the major route to elimina-
tion of resistin (15); therefore, resistin is elevated in patients with 
end-stage renal disease. Patients with anorexia nervosa had lower 
serum resistin levels (16-18), and serum resistin levels showed 
positive correlation with nPNA in dialytic patients (19), suggest-
ing that there may be a significant relationship between serum 
resistin and nutritional status. In our data, serum resistin levels 
were positively correlated with nPNA. It could be an explana-
tion that patients with low resistin levels had poor hospitaliza-
tion-free survival. In survival analysis, low levels of serum resis-
tin was a predictor of hospitalization. In addition, the group with 
highest quartile of serum resistin had also poor hospitalization-
free survival. It suggests that there may not be linear dose-re-
sponse relationship, but be U-shaped relationship between res-
itin levels and hospitalizaition. Kalantar-Zadeh et al. (20) indi-
cated that low levels of serum cholesterol or low levels of body 
mass index in the setting of under-nutrition are short-term mark-
ers of mortality in dialysis patients. Reverse epidemiology can 
exist in the relationship between short term clinical outcomes 
and serum resistin levels as a nutritional biomarker.
  Serum resistin levels were significantly correlated with value 
of nPNA; but the correlation coefficient was not strongly posi-
tive. It may be caused by mean value of nPNA in the group with 
4th quartile which was insignificantly lower than in the group 
with 3rd quartile. Resistin levels are reported inversely correlat-
ed with the protein catabolic rate in a small number cross-sec-
tional study (n = 33) (21). In contrast, resistin levels are positive-
ly correlated with body fat mass in a relatively large number cross-
sectional study (n = 114) (22). Further large-scaled clinical study 
may be needed.
  Barreto et al. (23) reported an association of interleukin-6 
with mortality in predialytic and dialytic patients. In this study, 
higher level of IL-6 was found to significantly increase the risk 
for poor hospitalization-free survival. In our data, no significant 
difference was observed between serum resistin levels and IL-6 
levels. Although resistin has a potential role in inflammation or 
cardiovascular disease (24, 25), most studies were cross-section-
al design. Few studies on resistin observed longitudinal clinical 
outcomes unlike studies on leptin or adiponectin. Some reports 
have shown no correlation between resistin and inflammatory 
cytokines (26, 27). It is possible that resistin levels may predict 
poor hospital-free survival independently of inflammation in 
our hemodialysis patients. 
  Many studies have used hospitalization as clinical predictor 
for outcome (28, 29). We chose hospitalization-free survival as 
clinical outcomes. Unfortunately, we failed to reveal the relation-
ship between resistin levels and death, or cardiovascular mor-
tality, because there were only 2 death and 10 admission events 
for cardiovascular disease during 1-yr observation period. We 
did not check other nutritional parameters including prealbu-
min, triceps/biceps skin-fold thickness. Since we measured 
levels of resistin only at the baseline, we had no data on change 
in serum resistin levels, which may have some different effects 
on hospitalization. To elucidate underlying mechanism of the 
potential link between resistin and nutrition or inflammation, 
further experimental or large-scale investigation may warrant.
  In conclusion, it is suggested that low resistin levels may pre-
dict poor hospitalization-free survival, independent of inflam-
mation markers in hemodialysis patients. 
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